Gentium SpA Upgraded to “Outperform” at Zacks (GENT)
Gentium SpA (NASDAQ:GENT) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a research report issued on Wednesday, American Banking News reports. The firm currently has a $30.50 target price on the stock. Zacks‘ price objective suggests a potential upside of 7.77% from the company’s current price.
Shares of Gentium SpA (NASDAQ:GENT) traded up 0.14% on Wednesday, hitting $28.34. The stock had a trading volume of 25,754 shares. Gentium SpA has a 1-year low of $6.96 and a 1-year high of $29.02. The stock has a 50-day moving average of $23.38 and a 200-day moving average of $13.42. The company has a market cap of $430.0 million and a price-to-earnings ratio of 96.92.
Gentium SpA (NASDAQ:GENT) last issued its quarterly earnings data on Tuesday, August 13th. The company reported $0.16 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.02 by $0.14. Analysts expect that Gentium SpA will post $0.45 EPS for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Brean Capital raised their price target on shares of Gentium SpA from $24.00 to $38.00 in a research note to investors on Monday, October 7th. They now have a “buy” rating on the stock. Separately, analysts at Wedbush raised their price target on shares of Gentium SpA from $20.00 to $35.00 in a research note to investors on Monday, September 30th. They now have an “outperform” rating on the stock.
Gentium S.p.A. is a biopharmaceutical company focused on the development and manufacture of defibrotide, a drug based on single-stranded deoxyribonucleic acid (NASDAQ:GENT) derived from pig intestines.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.